Fudan Zhangjiang Bio-Pharma Schedules 29 April 2026 Board Meeting to Approve Q1 2026 Unaudited Results

Bulletin Express

Apr 15

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited consolidated financial results for the first quarter ended 31 March 2026, followed by their public release.

The board currently comprises eight members: Executive Directors Mr. Zhao Da Jun (Chairman) and Ms. Xue Yan; Non-executive Directors Mr. Shen Bo and Ms. Yu Xiao Yang; Independent Non-executive Directors Mr. Wang Hong Guang, Mr. Lam Siu Wing, and Mr. Xu Pei Long; and Employee Director Ms. Qu Ya Nan.

The announcement was released in Shanghai on 15 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1150431751"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150431751\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150431751?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150431751","market":"us","top_or_hot":-1,"title":"Fudan Zhangjiang Bio-Pharma Schedules 29 April 2026 Board Meeting to Approve Q1 2026 Unaudited Results","media":"Bulletin Express","content":"<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited consolidated financial results for the first quarter ended 31 March 2026, followed by their public release.</p>\n<p>The board currently comprises eight members: Executive Directors Mr. Zhao Da Jun (Chairman) and Ms. Xue Yan; Non-executive Directors Mr. Shen Bo and Ms. Yu Xiao Yang; Independent Non-executive Directors Mr. Wang Hong Guang, Mr. Lam Siu Wing, and Mr. Xu Pei Long; and Employee Director Ms. Qu Ya Nan.</p>\n<p>The announcement was released in Shanghai on 15 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fudan Zhangjiang Bio-Pharma Schedules 29 April 2026 Board Meeting to Approve Q1 2026 Unaudited Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFudan Zhangjiang Bio-Pharma Schedules 29 April 2026 Board Meeting to Approve Q1 2026 Unaudited Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-15 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited consolidated financial results for the first quarter ended 31 March 2026, followed by their public release.</p>\n<p>The board currently comprises eight members: Executive Directors Mr. Zhao Da Jun (Chairman) and Ms. Xue Yan; Non-executive Directors Mr. Shen Bo and Ms. Yu Xiao Yang; Independent Non-executive Directors Mr. Wang Hong Guang, Mr. Lam Siu Wing, and Mr. Xu Pei Long; and Employee Director Ms. Qu Ya Nan.</p>\n<p>The announcement was released in Shanghai on 15 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01349","symbol_name":"复旦张江","start_time":0,"source_url":"","article_id":"1150431751","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150431751","pubTimestamp":1776247440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01349":"复旦张江"},"translate_title":"复旦张江生物制药定于2026年4月29日召开董事会批准2026年第一季度未经审计业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01349":1},"content_text":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited consolidated financial results for the first quarter ended 31 March 2026, followed by their public release.\nThe board currently comprises eight members: Executive Directors Mr. Zhao Da Jun (Chairman) and Ms. Xue Yan; Non-executive Directors Mr. Shen Bo and Ms. Yu Xiao Yang; Independent Non-executive Directors Mr. Wang Hong Guang, Mr. Lam Siu Wing, and Mr. Xu Pei Long; and Employee Director Ms. Qu Ya Nan.\nThe announcement was released in Shanghai on 15 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}